Our Blog

Mesoblast grants TiGenix global patent license

15 Dec 2017 – Developer of innovative cell-based medicines Mesoblast (ASX:MSB) grants biopharmaceutical company TiGenix an exclusive global patent license that enables the global commercialisation of its stem cell product.


Source: Finance News Network

Share this post